Kura Oncology

At the Cantor conference Kura Oncology reported a strong market launch of KOMZIFTI in NPM1‑mutated acute leukemia, capturing a majority share of new treatments in the second full quarter and achieving over 95% cost coverage within six months. The company plans to expand the pipeline with darlifarnib in solid tumors and expects four key data updates in the fourth quarter as well as initial phase III results from the KOMET‑017 study in 2028. Kura is founding Caspian Therapeutics to develop menin inhibitors for diabetes and will retain about 50% ownership. Management emphasized efficient capital allocation while pursuing two potential oncology blockbusters and estimates peak sales potential for ziftomenib at around $3 billion. » Więcej na de.investing.com

Kura Oncology said at the Wells‑Fargo conference that KOMZIFTI has seen strong market uptake, with $9.1 million net revenue in Q2 2024, 115 new patients and roughly 250 prescriptions. The company highlights two ongoing Phase‑III studies (KOMET‑017) with expected first topline results in 2028, as well as a broad solid‑tumor program for darlifarnib. Kura has about $518 million in cash and expects $180 million in milestone payments from Kyowa Kirin; its long‑term value will depend on further clinical data and regulatory steps. » Więcej na de.investing.com

Troy Edward Wilson purchased about 100,000 Kura Oncology shares on Aug. 24, 2026 at a weighted average price of $12.39, a $1.2 million transaction that raises his total beneficial ownership to roughly 1.2 million shares. The purchase increases his stake by about 9% and includes holdings via the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. The trade occurred with Kura Oncology at a $1.1 billion market cap; the company reported TTM revenue of $77.2 million and a net loss of $296.8 million. The article frames the insider buy as a potentially bullish signal for the stock. » Więcej na finance.yahoo.com